Literature DB >> 15721290

Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts.

Keizo Ohnaka1, Mizuho Tanabe, Hisaya Kawate, Hajime Nawata, Ryoichi Takayanagi.   

Abstract

To explore the mechanism of glucocorticoid-induced osteoporosis, we investigated the effect of glucocorticoid on canonical Wnt signaling that emerged as a novel key pathway for promoting bone formation. Wnt3a increased the T-cell factor (Tcf)/lymphoid enhancer factor (Lef)-dependent transcriptional activity in primary cultured human osteoblasts. Dexamethasone suppressed this transcriptional activity in a dose-dependent manner, while 1,25-dihydroxyvitamin D3 increased this transcriptional activity. LiCl, an inhibitor of glycogen synthase kinase-3beta, also enhanced the Tcf/Lef-dependent transcriptional activity, which was, however, not inhibited by dexamethasone. The addition of anti-dickkopf-1 antibody partially restored the transcriptional activity suppressed by dexamethasone. Dexamethasone decreased the cytosolic amount of beta-catenin accumulated by Wnt3a and also inhibited the nuclear translocation of beta-catenin induced by Wnt3a. These data suggest that glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts, partially through the enhancement of the dickkopf-1 production.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15721290     DOI: 10.1016/j.bbrc.2005.01.117

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  80 in total

Review 1.  Glucocorticoid-Induced Osteoporosis.

Authors:  Baruch Frenkel; Wendy White; Jan Tuckermann
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

Review 2.  Pathogenesis of osteoporosis: concepts, conflicts, and prospects.

Authors:  Lawrence G Raisz
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

Review 3.  Glucocorticoid-induced osteoporosis: 2019 concise clinical review.

Authors:  G Adami; K G Saag
Journal:  Osteoporos Int       Date:  2019-02-25       Impact factor: 4.507

Review 4.  Glucocorticoid-induced osteoporosis.

Authors:  Stuart L Silverman; Nancy E Lane
Journal:  Curr Osteoporos Rep       Date:  2009-03       Impact factor: 5.096

5.  Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice.

Authors:  Wei Yao; Zhiqiang Cheng; Cheryl Busse; Aaron Pham; Mary C Nakamura; Nancy E Lane
Journal:  Arthritis Rheum       Date:  2008-06

Review 6.  Management of glucocorticoid-induced osteoporosis.

Authors:  Juliet Compston
Journal:  Nat Rev Rheumatol       Date:  2010-02       Impact factor: 20.543

Review 7.  Adrenocortical incidentalomas and bone: from molecular insights to clinical perspectives.

Authors:  Barbara Altieri; Giovanna Muscogiuri; Stavroula A Paschou; Andromachi Vryonidou; Silvia Della Casa; Alfredo Pontecorvi; Martin Fassnacht; Cristina L Ronchi; John Newell-Price
Journal:  Endocrine       Date:  2018-08-02       Impact factor: 3.633

8.  High bone marrow fat in patients with Cushing's syndrome and vertebral fractures.

Authors:  Francesco Ferraù; Salvatore Giovinazzo; Erika Messina; Agostino Tessitore; Sergio Vinci; Gherardo Mazziotti; Andrea Lania; Francesca Granata; Salvatore Cannavò
Journal:  Endocrine       Date:  2019-08-02       Impact factor: 3.633

9.  Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment.

Authors:  A H van Lierop; A W van der Eerden; N A T Hamdy; A R Hermus; M den Heijer; S E Papapoulos
Journal:  J Clin Endocrinol Metab       Date:  2012-07-27       Impact factor: 5.958

10.  Silencing Dkk1 expression rescues dexamethasone-induced suppression of primary human osteoblast differentiation.

Authors:  Joseph S Butler; Joseph M Queally; Brian M Devitt; David W Murray; Peter P Doran; John M O'Byrne
Journal:  BMC Musculoskelet Disord       Date:  2010-09-15       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.